| Sponsor |
Protocol Code |
Trial Name |
Principal Investigator |
Phase |
Therapeutic Area |
Diseases and Conditions |
| Lilly |
I8F-MC-GPGN |
The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT) |
OĞUZHAN DEYNELİ (Prof.Dr.) |
Phase 2b |
Endocrinology, Diabetes and Metabolic Diseases |
Diabetes Mellitus |
| Boehringer Ingelheim |
1404-0040 |
A Phase 3, randomised, double-blind, parallel-group, event driven, cardiovascular safety study with BI 456906 administered
subcutaneously compared with placebo in participants with
overweight or obesity with established cardiovascular disease
(CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD |
DİLEK YAZICI (Prof.Dr.) |
Phase 3 |
Endocrinology, Diabetes and Metabolic Diseases |
Obesity and Cardiovascular Diseases |
| Syneos Health |
IMVT-1401-3202 |
A Phase 3, Multi-center, Randomized,
Quadruple-masked, Placebo-controlled Study of Batoclimab for
the Treatment of Participants with Active Thyroid Eye Disease
(TED) |
OĞUZHAN DEYNELİ (Prof.Dr.) |
Phase 3 |
Endocrinology, Diabetes and Metabolic Diseases |
Thyroid |
| Roche |
DC000129 |
Clinical study to evaluate the impact of the Accu-Chek SmartGuide CGM solution on the mean change in time in range of 70 - 180 mg/dl compared to SMBG |
OĞUZHAN DEYNELİ (Prof.Dr.) |
Medical Device |
Endocrinology, Diabetes and Metabolic Diseases |
Diabetes Mellitus |
| AMGEN |
20220196 |
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) |
DİLEK YAZICI (Prof.Dr.) |
Phase 3 |
Endocrinology, Diabetes and Metabolic Diseases |
Obesity and Cardiovascular Diseases |